The Lead Episode 121: A Discussion of Catheter Ablation or Antiarrhythmic Drugs for Ventricular Tachycardia, LIVE at HRX-A Discussion of Catheter Ablation or Antiarrhythmic Drugs for Ventricular Tachycardia, LIVE at HRX (Speaker Information)

A Discussion of Catheter Ablation or Antiarrhythmic Drugs for Ventricular Tachycardia, LIVE at HRX (Speaker Information)

Back to course

Pdf Summary

The discussion centers on the comparative use of catheter ablation versus antiarrhythmic drugs for treating ventricular tachycardia, referencing a key article published in the New England Journal of Medicine by the VANISH2 Study Team. The article is authored by a multi-disciplinary group of experts including John L. Sapp, M.D., William G. Stevenson, M.D., Jeff S. Healey, M.D., and others, who explored outcomes and therapeutic efficacy in managing ventricular tachycardia.<br /><br />The session is hosted by Dr. Jason T. Jacobson, MD, FHRS, from Westchester Medical Center, with contributions from Dr. J. Peter Weiss, MD, Msci, FHRS of Banner University of Arizona Medical Center, and Dr. Miguel Valderrabano, MD, PhD, FHRS of Houston Methodist Hospital. These experts bring clinical and research perspectives on the benefits and limitations of both treatment strategies.<br /><br />Disclosures include consulting, speaking, and research engagements with prominent device and pharmaceutical companies by Dr. Valderrabano, Dr. Weiss, and Dr. Jacobson, ensuring transparency regarding potential conflicts of interest.<br /><br />This discussion highlights current clinical practices in ventricular tachycardia management, focusing on when to opt for catheter ablation—a procedure that targets arrhythmogenic cardiac tissue—versus pharmacologic intervention with antiarrhythmic drugs. By examining evidence from the VANISH2 study and expert insights, the panel provides guidance on optimizing patient care, balancing efficacy, risks, and individual patient characteristics.<br /><br />Overall, the dialogue serves to inform cardiologists and electrophysiologists about evolving therapeutic options, empowering improved decision-making for managing ventricular tachycardia to enhance patient outcomes.

Keywords

ventricular tachycardia

catheter ablation

antiarrhythmic drugs

VANISH2 study

New England Journal of Medicine

John L. Sapp

William G. Stevenson

Jason T. Jacobson

J. Peter Weiss

Miguel Valderrabano